🔗 Share this article

As the US proceeds with historic adjustments to its immunization schedules, an unexpected name has emerged in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by casting doubt on Covid vaccinations during the global health crisis and has focused upon potential fatalities following COVID-19 immunization in her brief position at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Program

Agency leaders had intended to unveil sweeping revisions to the childhood immunization program recently, synchronizing the US with the Danish vaccine program, it is understood – a significant shift that would put the US at odds with a large portion of the international standard with no evidence for benefit. The planned update has been delayed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for ending some pediatric shot schedules in the US so as to align more similar to Denmark, a country with universal health coverage and a population roughly the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – typically the responsibility of Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent track record in drug development, oversight or administrative roles, which has been typical for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in managing a major agency. She has no expertise in drug approvals.”

Past heads of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she lacks the sort of resume that previous people who led the center have had.”

The drug center has an vast portfolio at the FDA, she pointed out.

“The public just focuses on the innovative therapies, but the generic program approves a multitude of generic drugs. There is also a biosimilars program, OTC medication office and so forth, and every single one have to be supervised,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major administrative component to the position, which oversees more than 5,000 staff members. “It is a enormous management job, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Policies

When asked about inquiries about Høeg’s credentials and whether this assignment signifies more teamwork among agency officials on vaccines, a representative said that the “concerns are based on incorrect premises”.

“Her resume is consistent with the responsibilities of her job,” the representative explained, noting the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s controversial expedited review system, a controversial rapid therapy clearance system that reportedly troubled her predecessors. “By what process are these therapies being picked for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards more relaxed oversight of all drugs, except for immunizations.”

Documented Past Work on Immunizations

Concerning immunizations, Høeg has a more established, if concerning, past, Howard observe. She published a study using unconfirmed volunteer-provided data to determine the rate of heart inflammation following COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming administration encompassed altering rules for new vaccines and ending “non-essential” immunizations, she said after the election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of excluding teenage boys from receiving Covid vaccinations.

“She’s an complete dogmatist who starts off with her preconceived notions and reverse-engineers to fit the evidence in a very misleading, fraudulent way,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|